TipRanks
Odonate (ODTC)
OTHER OTC:ODTC
US Market

Odonate (ODTC) Price & Analysis

289 Followers

ODTC Stock Chart & Stats

$150000.00
$5,005.00(29.44%)
At close: 4:00 PM EST
$150000.00
$5,005.00(29.44%)

ODTC FAQ

What was Odonate’s price range in the past 12 months?
Odonate lowest stock price was $150000.00 and its highest was $150000.00 in the past 12 months.
    What is Odonate’s market cap?
    Odonate’s market cap is $54.85B.
      When is Odonate’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Odonate’s earnings last quarter?
      Odonate released its earnings results on Nov 09, 2022. The company reported $1.363 earnings per share for the quarter.
        Is Odonate overvalued?
        According to Wall Street analysts Odonate’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Odonate pay dividends?
          Odonate does not currently pay dividends.
          What is Odonate’s EPS estimate?
          Odonate’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Odonate have?
          Odonate has 365,650 shares outstanding.
            What happened to Odonate’s price movement after its last earnings report?
            Odonate reported an EPS of $1.363 in its last earnings report. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Odonate?
              Currently, no hedge funds are holding shares in ODTC
              What is the TipRanks Smart Score and how is it calculated?
              Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                Company Description

                Odonate

                Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.

                Odonate (ODTC) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Exelixis
                Incyte
                Jazz Pharmaceuticals
                Regeneron
                Revolution Medicines
                Popular Stocks